Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lurasidone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | HTR7 | P34969 | 3/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lurasidone SCHEMBL12620240 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL2587434 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL19678283 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL15505744 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL2120201 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL17982546 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL16804108 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL10034018 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL21702794 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 | |
| Lurasidone SCHEMBL15978832 | 1.00 | DRD2 (1.00) | DRD2HTR2AHTR1ADRD3HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210290535-A1 | AQUEOUS SUSPENSION PREPARATION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-09-23 | — | — | US | claimed |
| EP-3760206-A1 | AQUEOUS SUSPENSION-TYPE PHARMACEUTICAL PREPARATION HAVING CONTROLLED DISSOLUTION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-01-06 | — | — | EP | claimed |
| EP-3760205-A1 | AQUEOUS SUSPENSION-TYPE PHARMACEUTICAL PREPARATION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2021-01-06 | — | — | EP | claimed |
| CN-111989102-A | Aqueous suspension type pharmaceutical preparation | 大日本住友制药株式会社 | 2020-11-24 | — | — | CN | claimed |
| CN-111989101-A | Aqueous suspension type pharmaceutical preparation with controlled dissolution | 大日本住友制药株式会社 | 2020-11-24 | — | — | CN | claimed |
| EP-3154967-B1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | JOHNSON MATTHEY PLC (GB) | 2020-07-29 | — | — | EP | claimed |
| EP-3508203-A1 | AQUEOUS SUSPENSION PREPARATION | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-07-10 | — | — | EP | claimed |
| EP-1944030-B1 | Agent for treatment of schizophrenia | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2018-08-01 | — | — | EP | claimed |
| US-20180051017-A1 | AGENT FOR TREATMENT OF SCHIZOPHRENIA | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-22 | — | — | US | claimed |
| US-9815827-B2 | Agent for treatment of schizophrenia | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-14 | — | — | US | claimed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | claimed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | claimed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | claimed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | claimed |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | claimed |
| EP-2295061-A1 | Agent for treatment of schizophrenia | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-03-16 | — | — | EP | claimed |
| EP-1535616-B1 | REMEDY FOR INTEGRATION DYSFUNCTION SYNDROME | DAINIPPON SUMITOMO PHARMA CO (JP) | 2009-05-13 | — | — | EP | claimed |
| EP-1944030-A1 | Agent for treatment of schizophrenia | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20060025422-A1 | Remedy for integration dysfunction syndrome | Sumitomo Pharma Co., Ltd. (JP) | 2006-02-02 | — | — | US | claimed |
| EP-1535616-A1 | REMEDY FOR INTEGRATION DYSFUNCTION SYNDROME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-06-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | DRD2 4460/4885HTR2A 4581/4885HTR1A 4680/4885 |
| US-20060025422-A1 | Remedy for integration dysfunction syndrome | GRIN2B, GRIN2A, GABRE | DRD2 193/4885HTR2A 150/4885HTR1A 221/4885 |
| US-20210290535-A1 | AQUEOUS SUSPENSION PREPARATION | IL17A, CYP3A7, CYP7B1 | DRD2 1154/4885HTR2A 359/4885HTR1A 48/4885 |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | DRD2 3458/4885HTR2A 4348/4885HTR1A 4433/4885 |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | DRD2 4460/4885HTR2A 4581/4885HTR1A 4680/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | DRD2 4238/4885HTR2A 4603/4885HTR1A 4599/4885 |
| US-20180051017-A1 | AGENT FOR TREATMENT OF SCHIZOPHRENIA | GRIN2B, GRIN2C, SLC6A3 | DRD2 22/4885HTR2A 197/4885HTR1A 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.